Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B.
The toxicology of liposome-encapsulated amphotericin B in mice and its efficacy in the treatment and prophylaxis of systemic candidiasis in these animals were studied. The toxicology studies indicated that the maximal tolerated dose of free amphotericin B was 0.8 mg/kg of body weight and the 50% lethal dose (LD50) was reached at 1.2 mg/kg, while neither the maximal tolerated dose nor the LD50 for the liposomal amphotericin B was reached at a dose of 12 mg/kg. No abnormalities in blood chemistry or histology were observed in the animals injected with encapsulated amphotericin B, while the administration of free amphotericin B was associated with nephrocalcinosis and renal parenchymal edema. The encapsulated drug was as effective as the free drug when used in similar concentrations, while the animals treated with higher concentrations of liposomal amphotericin B (4 mg/kg) had a longer survival time. Thus, an improved therapeutic index resulted by encapsulating amphotericin B in liposomes.
D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D000818:Animals; D002177:Candidiasis / Q000188:drug therapy* / Q000517:prevention & control; D004134:Dimyristoylphosphatidylcholine; D008081:Liposomes / Q000008:administration & dosage*; D051379:Mice; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols
D008081:Liposomes; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; D000666:Amphotericin B; C002773:dimyristoylphosphatidylglycerol; D004134:Dimyristoylphosphatidylcholine